Nasdaq CEO Expects Strong IPO Environment for Rest of the Year
Nasdaq Inc. Chief Executive Officer Adena Friedman said she expects a strong environment for initial public offerings in the second quarter and balance of 2025 as investors gain confidence from ...
5 Things to Know Before the Stock Market Opens
U.S. stock futures are little changed after Monday's tech selloff, Nvidia and other chipmaker stocks show signs of recovery after plunging on worries over China's AI capabilities, and General Motors ...
Dealbreaker on MSN2d
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World
Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...
Smithfield Foods, Inc IPOs Tomorrow, Here's What You Need To Know
Smithfield Foods, Inc SFD IPO will take place January, 28 on the NASDAQ exchange under the ticker SFD. The company is offering shares at an expected price between $23.00 and $27.00 per share with an ...
Factbox-IPO market comeback: How recent major US listings fared
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
8 Upcoming IPOs to Watch in 2025
As a result, Renaissance expects a banner year for IPOs, with an estimated volume range of 155 to 195 IPOs in 2025 and $40 billion to $55 billion in new funding as the market "normalizes" in 2025. "A ...
Two Massachusetts biotechs file to IPO post-JPM
A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...
Benzinga.com14d
What Analysts Are Saying About Vera Bradley Stock
Vera Bradley VRA has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their ...
Business Insider14d
Nuvini receives notification of Nasdaq listing non-compliance
The company has 60 calendar days, or until March 8, to either file the Annual Report or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the company does not file ...
Benzinga.com14d
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
5 analysts have shared their evaluations of Ionis Pharmaceuticals IONS during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their ...
Benzinga.com14d
5 Analysts Assess NeoGenomics: What You Need To Know
Ratings for NeoGenomics NEO were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...
Benzinga.com14d
Affirm Holdings's Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bearish stance on Affirm Holdings AFRM. And retail traders should know. We noticed this today when the trades showed up on publicly available ...